Pharsight

Vraylar patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7943621 ALLERGAN Salts of piperazine compounds as D3/D2 antagonists
Dec, 2028

(5 years from now)

US7737142 ALLERGAN (Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists
Sep, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE47350 ALLERGAN Pharmaceutical formulations containing dopamine receptor ligands
Jul, 2029

(5 years from now)

USRE49110 ALLERGAN Pharmaceutical formulations containing dopamine receptor ligands
Jul, 2029

(5 years from now)

Vraylar is owned by Allergan.

Vraylar contains Cariprazine Hydrochloride.

Vraylar has a total of 4 drug patents out of which 0 drug patents have expired.

Vraylar was authorised for market use on 17 September, 2015.

Vraylar is available in capsule;oral dosage forms.

Vraylar can be used as treatment of depressive episodes associated with bipolar i disorder (bipolar depression) with cariprazine; treatment of acute manic or mixed episodes associated with bipolar i disorder with cariprazine; treatment of schizophrenia with cariprazine, treatment of acute manic or mixed episodes associated with bipolar i disorder with cariprazine; treatment of depressive episodes associated with bipolar i disorder (bipolar depression) with cariprazine; treatment of schizophrenia and/or acute manic or mixed episodes associated with bipolar i disorder with cariprazine; treatment of schizophrenia with cariprazine, treatment of schizophrenia and/or acute manic or mixed episodes associated with bipolar i disorder with cariprazine; treatment of schizophrenia with cariprazine; treatment of acute manic or mixed episodes associated with bipolar i disorder with cariprazine; treatment of depressive episodes associated with bipolar i disorder (bipolar depression) with cariprazine.

The generics of Vraylar are possible to be released after 17 September, 2029.

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Dec 16, 2025

Drugs and Companies using CARIPRAZINE HYDROCHLORIDE ingredient

Market Authorisation Date: 17 September, 2015

Treatment: Treatment of schizophrenia and/or acute manic or mixed episodes associated with bipolar i disorder with cariprazine; Treatment of schizophrenia with cariprazine; Treatment of acute manic or mixed epis...

Dosage: CAPSULE;ORAL

How can I launch a generic of VRAYLAR before it's drug patent expiration?
More Information on Dosage

VRAYLAR family patents

Family Patents
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE49302 ABBVIE Pharmaceutical formulations containing dopamine receptor ligands
Jul, 2029

(5 years from now)

Vraylar is owned by Abbvie.

Vraylar contains Cariprazine Hydrochloride.

Vraylar has a total of 1 drug patent out of which 0 drug patents have expired.

Vraylar was authorised for market use on 17 September, 2015.

Vraylar is available in capsule;oral dosage forms.

Vraylar can be used as treatment of schizophrenia with cariprazine; adjunctive therapy to antidepressants for the treatment of major depressive disorder; treatment of acute manic or mixed episodes associated with bipolar i disorder with cariprazine; treatment of depressive episodes associated with bipolar i disorder (bipolar depression) with cariprazine.

The generics of Vraylar are possible to be released after 16 July, 2029.

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Dec 16, 2025

Drugs and Companies using CARIPRAZINE HYDROCHLORIDE ingredient

Market Authorisation Date: 17 September, 2015

Treatment: Treatment of schizophrenia with cariprazine; Adjunctive therapy to antidepressants for the treatment of major depressive disorder; Treatment of acute manic or mixed episodes associated with bipolar i ...

Dosage: CAPSULE;ORAL

How can I launch a generic of VRAYLAR before it's drug patent expiration?
More Information on Dosage

VRAYLAR family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic